# EANO 2018 ramme OCTOBER 10 - 14, 2018 13<sup>™</sup> MEETING & Educational Day




www.eano.eu

## EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

STOCKHOLM, SWEDEN

Stockholm Waterfront Congress Centre Stockholm, Sweden

### **FLOORPLANS**



EVENT	ROOM	EVENT	ROOM
EANO-SNO Brain Tumor Club	C1-C3	EANO Meeting - Lecture Halls	A2, A3+A4, C1-C3, C4
Special Lecture & Get Together	C1-C3	Preview Centre	27
Educational Day	A2	Side Meetings	26
Educational Day for Nurses & AHPs	C4	Board Room	23

## TABLE OF CONTENTS







#### **GENERAL**

Welcoming Address2
$Committees-Board-Organisation\ \dots\dots\dots.3$
Accreditation & Future Meetings
SCIENTIFIC PROGRAMME
Programme at a Glance
Detailed Scientific Programme
EANO – SNO Brain Tumor Club
Wednesday, October 10
EANO – EORTC Educational Day
Wednesday, October 10 & Thursday, October 119
Nurse – Educational Day
Thursday, October 1110
EANO Meeting
Friday, October 12
Saturday, October 13
Sunday, October 14
Side Meetings
SCIENTIFIC INFORMATION
Oral Presentations
Poster Viewing
Poster Viewing



#### **WELCOMING ADDRESS**

DEAR COLLEAGUES, DEAR FRIENDS,



It is now a great honor and privilege to welcome you all to the  $13^{\text{th}}$  EANO meeting, here in Stockholm, Sweden. from 10 - 14 October, 2018. We are looking forward to an educational and inspirational meeting with the ultimate goals of improving the life of patients strucken by a brain tumour.

Stockholm with Karolinska Institute, as one of several universities in Sweden, and the Nobel Price is dedicated to excellent basic, translational and clinical cancer research. Stockholm is an attractive capital that offers something for everyone: culture, nature, indulgence and an excellent infrastructure. Furthermore, the great transportation network in Sweden and to the whole Nordic area gives the possibilities to taste an interesting and beautiful part of Europe.



The whole EANO programme from beginning to end, has a lot to offer attendes from various backgrounds. Whether you as an individual are a clinician, a scientist, a nurse, from other professions or a patient advocacy group, and whether you are new to brain tumours or very experienced, you will find presentations that increase your knowledge. Most valuable, the speakers are from many countries and institutions with a plethora of experiences which fruitfully will contribute to make the EANO 2018 a successfull meeting.

We really hope that this meeting will be something to inspire the future collaboration and research in the field of neuro-oncology, and that we all acknowledge the need of both top research and of diversity even in the field of science.

We wish you a pleasant time.

Welcome to Stockholm and the EANO meeting 2018!

All the Best,

Roger Henriksson

President EANO 2018 Meeting

Wolfgang Wick President EANO

Wolfgan, W)



#### **COMMITTEES – BOARD – ORGANISATION**

#### **EANO Scientific Committee**

#### Congress President

Roger Henriksson, Umeå/SE

#### Local Coordinator

Monica Sandström, Umeå/SE

#### Chair

Roger Henriksson, Umeå/SE

#### Members

Carmen Balaña Quintero, *Barcelona/ES*Hugues Duffau, *Montpellier/FR*Jaima Cállaga Páraz do Larraya, *Pamplana/I* 

Jaime Gállego Pérez de Larraya, Pamplona/ES

Alan Jackson, *Manchester/UK* Emilie Le Rhun, *Lille/FR* 

Silvia Marino, London/UK

Stephan Pfister, Heidelberg/DE

Karin Piil, Copenhagen/DK

Zvi Ram, Tel Aviv/IL

Guido Reifenberger, Duesseldorf/DE

Patrick Roth, Zurich/CH

Salvador Villà i Freixa, Barcelona/ES

#### **EANO Executive Board**

President: Wolfgang Wick, *Heidelberg/DE*Past President: Michael Weller, *Zurich/CH*Treasurer: Geoffrey Pilkington, *Ryde/UK* 

#### **EANO Board Members**

Elizabeth Cohen-Jonathan Moyal, Toulouse/FR

Roger Henriksson, *Umeå /SE* Jérôme Honnorat, *Lyon/FR* Matthias Preusser, *Vienna/AT* 

Guido Reifenberger, Duesseldorf/DE

Robert Rudà, Turin/IT

Martin van den Bent, *Rotterdam/NL* Colin Watts, *Birmingham/UK* 

#### **Nurse Board Member**

Ingela Oberg, Cambridge/UK

#### **EANO Office**

c/o WMA GmbH Ms. Magdalena Mara Alser Strasse 4 1090 Vienna, Austria T: +43 1 405 13 83-31

E: office@eano.eu www.eano.eu



#### **Exhibition and Advertisements**

WMA GmbH Ms. Anja Rosenkranz Alser Strasse 4

1090 Vienna, Austria

T: +43 1 405 13 83-27

E: eano-meetings@eano.eu

#### **EANO 2018 Conference Secretariat**

c/o WMA GmbH Ms. Anja Rosenkranz Alser Strasse 4 1090 Vienna, Austria

T: +43 1 405 13 83-27 E: eano-meetings@eano.eu



#### Venue of EANO 2018

Stockholm Waterfront Congress Centre

Nils Ericsons Plan 4 Stockholm, Sweden

T: +46 8 5050 6540

www.stockholmwaterfront.com



#### **ACCREDITATION & FUTURE MEETINGS**

#### **CME CREDITS**

The 13<sup>th</sup> Meeting of the European Association of Neuro-Oncology, Stockholm, Sweden, October 10 - 14, 2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 25 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of *AMA PRA Category 1 Credits™*. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation\* at the event once he/she has completed the post-congress evaluation form. (Cf. criteria 9 and 23 of UEMS 2016.20)

The EACCME® credit system is based on 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day.

\*Please get your badge scanned every day at the registration desk. The Certificate of Attendance will indicate the number of CME credits that correspond with your badge scans.

### **FUTURE CONFERENCES**



**EANO 2019** September 19-22, 2019 | Centre de Congrès, Lyon (FRANCE)

EANO 2020 September 10-13, 2020 | Scottish Event Campus, Glasgow (UNITED KINGDOM)

More information will be available online at www.eano.eu closer to the conferences.

## SCIENTIFIC PROGRAMME







Programme at a Glance
Detailed Scientific Programme
EANO – SNO Brain Tumor Club Wednesday, October 10
EANO – EORTC Educational Day Wednesday, October 10 & Thursday, October 119
Nurse – Educational Day Thursday, October 11
<b>EANO Meeting</b> Friday, October 12
Saturday, October 13
Side Meetings



## **PROGRAMME AT A GLANCE**

	Wed, Oct. 10	Thursday,	October 11		Friday, O	ctober 12	
Room	C1-C3	A2	C4	A3 + A4	A2	C1-C3	C4
Level	2	6	2	6	6	2	2
7:00 – 07:15		Educational Day	Educational Day for				
7:15 – 07:30			Nurses and AHPs			<del></del>	
7:30 – 07:45 7:45 – 08:00							
8:00 – 08:15				08:00 - 08:55			
8:15 – 08:30			······································	Wake Up Session 1	08:00 - 08:55 <b>Wake Up Session 2</b>	08:00 - 08:55 Wake Up Session 3	
8:30 – 08:45				Controversies in non-surgical	Controversis	Controversies in basic science	
08:45 - 09:00		Welcome address and introduction		treatment	in surgery	III basic science	
9:00 – 09:15			Welcome & Introductions	09:00 - 10:20	09:00 - 10:20	09:00 - 10:20	
9:15 – 09:30		Brain tumors in	Introductions	Meet the Expert Session 1	Meet the Expert Session 2	Meet the Expert Session 3	
9:30 – 09:45 9:45 – 10:00		children vs. adults - Updates on basic	In double nouse	Update in the management of adult	Clinical	Molecular and cellular	
0:00 - 10:15		science and clinic	In depth neuro- radiology teaching	high-grade glioma	psycho-neuro-oncology	biology of brain tumors	
0:15 – 10:30					10:20 - 10:50	<u> </u>	
0:30 – 10:45		Coffee break	Coffee break		Coffee break		
0:45 – 11:00			Conce piedk				
1:00 - 11:15		Brain tumors in children vs. adults	Hope and end of life care: a parent's perspective				
1:15 – 11:30 1:30 – 11:45		Updates on basic science and clinic		10:50 - 12:45	10:50 - 12:45	10:50 - 12:45	10:50 - 12:45
1:45 – 12:00		science and chinc	Supporting family caregivers in SE and DK	Oral Session 1 Basic science and	Oral Session 2	Concurrent Session 1	Concurrent Session 2
2:00 – 12:15			UK Family / caregivers	pathology	Non-surgical treatment	Surgery	Nursing perspective
2:15 – 12:30		Lunch break	weekend				
2:30 – 12:45							
2:45 – 13:00			Lunch break				
3:00 - 13:15					12:50 - 14:20		
3:15 - 13:30		Cancer registries:		12:50 - 14:20 Lunch break	Corporate Lunch	12:50 - 14:20 <b>Lunch break</b>	
3:30 - 13:45 3:45 - 14:00	·	from research to	Whole-person care and neuro-oncology	Lunch break	Symposium	Lunch break	
4:00 - 14:15		clinical support					
4:15 – 14:30	· ··········		Caring for the caregiver				L
4:30 – 14:45		Coffee break	Quality of care in adolescents and young	Welcome & presidential addr.			
4:45 – 15:00		Conce bleak	adults (AYA) with cancer	14:45 - 15:25			
5:00 - 15:15			Coffee break	Opening Lecture			
5:15 – 15:30 5:30 – 15:45	·						
5:45 – 16:00		Update on non-glial	Managing patient and				
6:00 – 16:15		CNS tumors	caregivers expectations	15:30 - 16:55 Plenary Session 1	15:30 - 16:55	15:30 - 16:55 Plenary Session 3	
6:15 – 16:30				Immunogenicity and immunotherapy	Plenary Session 2 Nurse Session	Pediatric neuro- oncology	
6:30 – 16:45			Different voices of patients and spouses in cases of	пппипоспетару		oncology	
6:45 – 17:00			malignant glioma				
7:00 – 17:15 7:15 – 17:30	EANO-SNO Brain Tumor Club	Neuro-oncology research in Europe? Who is in the lead?	Closing remarks & discussion				
7:30 – 17:45				Poster Vi	17:00 - 18:00 lewing <b>1 - with wine ar</b>	nd cheese	
7:45 – 18:00	,-		•••••••••••••••••••••••••••••••••••••••				
8:00 – 18:15							
8:15 – 18:30							
8:30 – 18:45		18.00	- 20:00				
8:45 – 19:00			ing Event				
9:00 – 19:15 9:15 – 19:30			nolm City Hall				
9:30 – 19:45							
9:45 – 20:00	Special Lecture &					– 22:00	
20:00 – 20:15	Get together					- 22:00 FERS Networking	
20:15 – 20:30					in the Confe	rence Lounge	
0:30 – 20:45					in the Radisson	Blu Royal Viking	
0:45 - 21:00							
1:00 – 21:15							
1:15 – 21:30							



## **PROGRAMME AT A GLANCE**

Saturday, October 13			Sunday, C	October 14	
A3 + A4	A2	C1-C3	C1-C3	C4	Room
6	6	2	2	2	Level
		_	_	_	07:00 - 07:15
					07:15 - 07:30
					07:30 - 07:45
					07:45 - 08:00
08:00 - 08:55 Wake Up Session 4	08:00 - 08:55	08:00 - 08:55			08:00 - 08:15
Novel approaches	Wake Up Session 5 Trial design and outome	Wake Up Session 6			08:15 - 08:30
of molecular tumor classification	measuers	Enhancing patient care	08:30 - 09:25		08:30 - 08:45 08:45 - 09:00
	00.00 10.00		EANO General Assembly		09:00 - 09:15
09:00 - 10:20 Meet the Expert	09:00 - 10:20 Meet the Expert		deficial Assembly		09:15 - 09:30
Session 4 CNS metastasis:	Session 5 Update in the management				09:30 - 09:45
from basic science to	of meningioma and benign		09:30 - 10:30	09:30 - 10:30	09:45 – 10:00
clinical trials	tumours		Ethical issues	Experimental models	10:00 - 10:15
	10:20 - 10:50				10:15 – 10:30
	Coffee break		EORTC Brain tumor studies	Coffee break	10:30 - 10:45
			Brain tumor studies	LEVEL 2	10:45 - 11:00
					11:00 - 11:15
10:50 - 12:45	10:50 - 12:45	10:50 - 12:45	11:10 - 12:35	11:10 - 12:10	11:15 – 11:30 11:30 – 11:45
Oral Session 3  Molecular genetics and	Oral Session 4	Oral Session 5	EANO Youngsters	Oral Session 6	11:45 – 12:00
epigenetics	Supportive care	Pediatric brain tumors	<b>Session</b> Perspectives	General clinical neuro-oncology	12:00 – 12:15
			in neuro-oncology	nearo oncology	12:15 – 12:30
					12:30 – 12:45
			Awards & Closing remarks – From president to president		12:45 – 13:00
					13:00 – 13:15
12:50 - 14:20	12:50 - 14:20 Corporate Lunch	12:50 - 14:20			13:15 – 13:30
Lunch break	Symposium	Lunch break		•••••	13:30 – 13:45
					13:45 - 14:00
					14:00 – 14:15 14:15 – 14:30
					14:30 – 14:45
14:25 - 15:45 Plenary Session 4	14:25 - 15:45	14:25 - 15:45			14:45 – 15:00
Management of adult	Plenary Session 5	Plenary Session 6			15:00 – 15:15
and pediatric low grade gliomas	Treatment resistance	Basic immunology			15:15 – 15:30
giloillas				•	15:30 – 15:45
15:50 - 17:15					15:45 – 16:00
Better and					16:00 – 16:15
knowledgeable patients -				••••••	16:15 – 16:30
better decisions -					16:30 – 16:45 16:45 – 17:00
better outcomes					17:00 – 17:15
					17:15 – 17:30
	17:15 - 18:15				17:30 – 17:45
Poster '	Viewing 2 - with wine and	cheese			17:45 – 18:00
					18:00 – 18:15
·····					18:15 - 18:30
					18:30 – 18:45
					18:45 – 19:00 19:00 – 19:15
					19:15 – 19:30
					19:30 – 19:45
					19:45 – 20:00
	19:00 – 23:00				20:00 – 20:15
	EANO Evening in the Grand Hôtel			•••••	20:15 – 20:30
					20:30 – 20:45
					20:45 - 21:00
					21:00 - 21:15
			Fax ayaat t	imes please see Detailed Scie	21:15 - 21:30










### **WEDNESDAY, OCTOBER 10**

#### **EANO - SNO BRAIN TUMOR CLUB**

#### Wednesday, October 10

Room: C1-C3







## WEDNESDAY, OCTOBER 10 & THURSDAY, OCTOBER 11

#### **EANO – EORTC EDUCATIONAL DAY**

Aron Andersson, Stockholm/SE

#### Wednesday, October 10



#### Thursday, October 11

Room: A2

08:45 - 09:00	Welcome address and introduction Michael Weller, Zurich/CH; Wolfgang Wick, Heidelberg/DE
09:00 - 10:20	Brain tumors in children vs. adults – Updates on basic science and clinic Chairs: Maria Sandström, Umeå/SE; Wolfgang Wick, Heidelberg/DE
09:00 - 09:20	Gliomas in children; Stefan Pfister, Heidelberg/DE
09:20 – 09:40	Gliomas in adults; Martin van den Bent, Rotterdam/NL
09:40 – 10:00	Medulloblastoma in children; Christelle Dufour, Villejuif/FR
10:00 – 10:20	Medulloblastoma in adults; Peter Hau, Regensburg/DE
10:30 - 11:00	Coffee break
11:00 – 11:45	Brain tumors in children vs. adults – Updates on basic science and clinic Chairs: Maria Sandström, Umeå/SE; Wolfgang Wick, Heidelberg/DE
11:00 – 11:20	Ependymal tumors in adults and childhood – Molecular genetics and classification; Hendrik Witt, Heidelberg/DE
11:20 – 11:40	Ependymal tumors in adults and childhood – Clinical view and treatment (EANO guidelines); Roberta Rudà, Turin/IT
11:45 – 13:00	Lunch break
13:00 – 14:30	Cancer registries: from research to clinical support Chairs: Roger Henriksson, Umeå/SE; Jaap Reijneveld, Amsterdam/NL
13:00 – 13:18	Cancer registries in Sweden from 1958 and onwards – research, clinic, and patient outcome with focus on CNS tumours; Beatrice Melin, Umeå/SE
13:18 – 13:36	Patient perspective and cancer registries; Helen Bulbeck, Cowes/UK
13:36 – 13:54	The Canton of Zurich Registry 1980-2015; Dorothee Gramatzki, Zurich/CH
13:54 – 14:12	The Dutch Brain Tumor registration; Jaap Reijneveld, Amsterdam/NL
14:12 – 14:30	How to leverage cancer registry data for advancing patient care; Jill Barnholtz-Sloan, Cleveland/US
14:30 – 15:00	Coffee break
15:00 – 17:00	Update on non-glial CNS tumors Chairs: Hanna Mäenpää, Helsinki/FI; Michal Weller, Zurich/CH
15:00 - 15:30	Primary central nervous system lymphoma; Khê Hoang-Xuan, Paris/FR
15:30 – 16:00	Molecular pathogenesis of CNS germ cell tumors; Koichi Ichimura, Tokyo/JP
16:00 – 16:30	Management of spinal intradural tumours (extra- and intramedullary), surgical details and the role of post-operative oncological treatment; <i>Niklas Marklund, Lund/SE</i>
16:30 – 17:00	Aspects on optimization of radiotherapy in combination with targeted drygs and immunotherapy; Elizabeth Cohen-Jonathan Moyal, Toulouse/FR
17:00 – 17:30	What about the neuro-oncology research in Europe? Who is in the lead? Rickard Danell, Umeå/SE
18:00 – 20:00	Networking Event in the Stockholm City Hall



## **THURSDAY, OCTOBER 11**

## **NURSE – EDUCATIONAL DAY**

#### Thursday, October 11

Room: C4

09:00 - 10:30	Nurse Education 1 Chairs: Ingela Oberg, Cambridge/UK; Karin Piil, Copenhagen/DK
09:00 – 09:20	Welcome & Introductions Ingela Oberg, Cambridge/UK
09:20 – 09:30	Introduction from TBTC Sacha Langton-Gilks, Shaftesbury/UK
09:30 – 10:30	In depth neuro-radiology teaching (T1 v T2; DWI; Gad; perfusion sequencing etc.) David Summers, Edinburgh/UK
10:30 - 11:00	Coffee break
11:00 – 12:30	Nurse Education 2 Chairs: Ingela Oberg, Cambridge/UK; Karin Piil, Copenhagen/DK
11:00 – 11:30	Hope and end of life care: a parent's perspective Sacha Langton-Gilks, Shaftesbury/UK
11:30 – 12:00	Supporting family caregivers in Sweden and Denmark Eskil Degsell, Stockholm/SE; Karin Piil, Copenhagen/DK; Lena Rosenlund, Stockholm/SE
12:00 – 12:30	UK Family / caregivers weekend Tina Mitchell-Skinner, Thornbury/UK
12:30 – 13:30	Lunch break
13:30 – 15:00	Nurse Education 3 Chairs: Ingela Oberg, Cambridge/UK; Lena Rosenlund, Stockholm/SE
13:30 – 14:00	Whole-person care and neuro-oncology Ros Taylor, Hertfordshire/UK
14:00 – 14:30	Caring for the caregiver  Margaretta Page, San Francisco/US
14:30 – 15:00	Quality of care in adolescents and young adults (AYA) with cancer Jane Robson, Cambridge/UK
15:00 – 15:30	Coffee break
15:30 – 17:15	Nurse Education 4 Chairs: Ingela Oberg, Cambridge/UK; Lena Rosenlund, Stockholm/SE
15:30 – 16:30	Managing patient and caregivers expectations Helen Bulbeck, Cowes/UK
16:30 – 17:00	Different voices of patients and spouses in cases of malignant glioma Pär Salander, Umeå/SE
17:00 – 17:15	Closing remarks & discussion Ingela Oberg, Cambridge/UK; Lena Rosenlund, Stockholm/SE; Karin Piil, Copenhagen/DK







Networking Event in the Stockholm City Hall

18:00 – 20:00



#### EANO MEETING

#### Friday, October 12

08:00 - 08:55



Wake up Session 1 - Controversies in non-surgical treatment







Supportive care in the short term and long term from a medical and supportive care view

09:20 - 09:40

09:40 - 10:00

10:00 - 10:20

Diagnosis and treatment Sara Kinhult, Lund/SE

What next?

Robin Grant, North Berwick/UK

Olivier Chinot, Marseille/FR



09:00 – 10:20	Meet the expert Session 2 – Clinical psycho-neuro-oncology Room: A2
	Chairs: Karin Gehring, Tilburg/NL; Pär Salander, Umeå/SE
09:00 – 09:20	Hope work is facilitated by the establishment of a helping plan Pär Salander, Umeå/SE
09:20 – 09:40	Psychiatric symptoms and emotional distress in cases of brain tumours Ally Rooney, Edinburgh/UK
09:40 – 10:00	Endpoints in brain tumor clinical trials and their value in clinical care Linda Dirven, Leiden/NL
10:00 - 10:20	Rehabilitation of cognitive deficits in brain tumors Karin Gehring, Tilburg/NL
09:00 – 10:20	Meet the expert Session 3 – Molecular and cellular biology of brain tumors Room: C1-C3
	Chairs: Silvia Marino, London/UK; Lene Uhrbom, Uppsala/SE
09:00 – 09:25	Molecular mechanisms driving glioma recurrence  Guido Reifenberger, Duesseldorf/DE
09:25 – 09:50	Metabolic alterations driving glioma pathogenesis Sevin Turcan, Heidelberg/ DE
09:50 – 10:15	Lessons learned from platelet RNA Nik Sol, Amsterdam/NL
10:20 – 10:50	Coffee break
10:50 - 12:45	Oral Session 1 – Basic science and pathology Room: A3+A4
	Chairs: Håkan Hedman, Umeå/SE; Simon Niclou, Luxembourg/LU
10:50 – 11:15	
10:50 – 11:15 11:15 – 11:27	Chairs: Håkan Hedman, Umeå/SE; Simon Niclou, Luxembourg/LU Key Lecture
	Chairs: Håkan Hedman, Umeå/SE; Simon Niclou, Luxembourg/LU Key Lecture Simon Niclou, Luxembourg/LU Role of RNU6-1 isolated from circulating exosomes as a differential biomarker for GBM versus non-neoplasic brain lesions and PCNSL
11:15 – 11:27	Chairs: Håkan Hedman, Umeå/SE; Simon Niclou, Luxembourg/LU  Key Lecture Simon Niclou, Luxembourg/LU  Role of RNU6-1 isolated from circulating exosomes as a differential biomarker for GBM versus non-neoplasic brain lesions and PCNSL Montserrat Puigdelloses, Pamplona/ES  Stability of EGFR amplification in glioblastoma is differentially impacted based on therapeutic pressure Manmeet Ahluwalia, Westlake/US  Clinical significance of plasma EVs in glioblastoma patients
11:15 – 11:27 11:27 – 11:39	Chairs: Håkan Hedman, Umeå/SE; Simon Niclou, Luxembourg/LU Key Lecture Simon Niclou, Luxembourg/LU Role of RNU6-1 isolated from circulating exosomes as a differential biomarker for GBM versus non-neoplasic brain lesions and PCNSL Montserrat Puigdelloses, Pamplona/ES Stability of EGFR amplification in glioblastoma is differentially impacted based on therapeutic pressure Manmeet Ahluwalia, Westlake/US
11:15 - 11:27 11:27 - 11:39 11:39 - 11:51	Chairs: Håkan Hedman, Umeå/SE; Simon Niclou, Luxembourg/LU  Key Lecture Simon Niclou, Luxembourg/LU  Role of RNU6-1 isolated from circulating exosomes as a differential biomarker for GBM versus non-neoplasic brain lesions and PCNSL Montserrat Puigdelloses, Pamplona/ES  Stability of EGFR amplification in glioblastoma is differentially impacted based on therapeutic pressure Manmeet Ahluwalia, Westlake/US  Clinical significance of plasma EVs in glioblastoma patients Massimiliano Del Bene, Milan/IT Induction of mitotic cell death: a novel therapeutic strategy for glioblastoma
11:15 - 11:27 11:27 - 11:39 11:39 - 11:51 11:51 - 12:03	Chairs: Håkan Hedman, Umeå/SE; Simon Niclou, Luxembourg/LU Key Lecture Simon Niclou, Luxembourg/LU Role of RNU6-1 isolated from circulating exosomes as a differential biomarker for GBM versus non-neoplasic brain lesions and PCNSL Montserrat Puigdelloses, Pamplona/ES Stability of EGFR amplification in glioblastoma is differentially impacted based on therapeutic pressure Manmeet Ahluwalia, Westlake/US Clinical significance of plasma EVs in glioblastoma patients Massimiliano Del Bene, Milan/IT Induction of mitotic cell death: a novel therapeutic strategy for glioblastoma Natividad Gomez-Roman, Glasgow/UK Harnessing soluble LRIG1 for pan-RTK targeting in glioblastoma



10:50 – 12:45	Oral Session 2 – Non-surgical treatment Room: A2
	Chairs: Matthias Preusser, Vienna/AT; Aleksandar Stanimirovic, Belgrade/RS
10:50 - 11:15	Key Lecture  Matthias Preusser, Vienna/AT
11:15 – 11:27	Objective responses to chemotherapy in recurrent glioma do not predict better survival: A prospective analysis from the German Glioma Network Oliver Bähr, Frankfurt/DE
11:27 – 11:39	Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial Pierre-Yves Dietrich, Geneva/CH
11:39 – 11:51	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma <gbm> patients <pts> Giuseppe Lombardi, Padua/IT</pts></gbm>
11:51 – 12:03	Angiotensin II Receptor Blockers, steroids and radiotherapy in glioblastoma - A randomized multicenter trial (ASTER Trial). An ANOCEF Study Antoine Carpentier, Paris/FR
12:03 – 12:15	Effect of rituximab in primary central nervous system lymphoma - results of the randomized phase III HOVON 105/ALLG NHL 24 study Jacoline Bromberg, Rotterdam/NL
12:15 – 12:27	Cerebrospinal fluid (CSF) plays a crucial role in the pathogenesis and treatment of patients with brain metastases  Ayesha Ali, New York/US
10:50 - 12:45	Concurrent Session – Surgery Room: C1-C3
	Chairs: Peter Milos, Linkoeping/SE; Jane Skjøth-Rasmussen, Copenhagen/DK
10:50 – 11:07	Maximising extent of resection in glioma surgery in clinical trials  Colin Watts, Birmingham/UK
11:07 – 11:24	Is awake craniotomy feasible for children?  Margret Jensdottir, Stockholm/SE
11:24 – 11:41	Endoscopy as an adjunct to glioma surgery: current evidence  Puneet Plaha, Oxford/UK
11:41 – 11:58	Non-invasive surgical approaches  Clemens Dirven, Rotterdam/NL
11:58 – 12:15	Molecular imaging for surgical planning  Jörg-Christian Tonn, Munich/DE
12:15 – 12:32	Glioma surgery in the elderly patient


Peter Milos, Linkoeping/SE



10:50 – 12:45	Concurrent Session – Nursing perspective Room: C4
	Chairs: Anders Hansen, Odense/DK; Mary Lovely, San Francisco/US
10:50 – 11:07	A 12-week interdisciplinary rehabilitation trial in patients with gliomas – a feasibility study Anders Hansen, Odense/DK
11:07 – 11:24	Patients' and health care's perspectives on the increasing use of complementary and alternative medicine (CAM).  Kathrin Wode, Stockholm/SE
11:24 – 11:41	Patient reported outcomes of the brain tumour quality registry  Lena Rosenlund, Stockholm/SE
11:41 – 11:58	Milton Marks Family Camp Mary Lovely, San Francisco/US
11:58 – 12:15	Collecting and using quality of life data in neuro-oncology practice  Rocio Fernandez Mendez, Cambridge/UK
12:15 – 12:32	Ketogenic diet – fact or fiction?  Michael Jenkinson, Liverpool/UK
12:50 – 14:20	Corporate Lunch Symposium Room: A2
	see page 30
12:50 – 14:20	Lunch break
14:30 – 14:45	Welcome and presidential address
14.50 14.45	Room: A3+A4
14.50	
14:45 – 15:25	Room: A3+A4
	Room: A3+A4  Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Opening Lecture
	Room: A3+A4  Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Opening Lecture Room: A3+A4
	Room: A3+A4  Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Opening Lecture Room: A3+A4  Chairs: Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Brain Tumor Classification – From WHO 2016 to current status and beyond
14:45 – 15:25	Room: A3+A4  Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Opening Lecture Room: A3+A4  Chairs: Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Brain Tumor Classification – From WHO 2016 to current status and beyond Andreas von Deimling, Heidelberg/DE  Plenary Session 1 – Immunogenicity and immunotherapy
14:45 – 15:25	Room: A3+A4  Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Opening Lecture Room: A3+A4  Chairs: Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Brain Tumor Classification – From WHO 2016 to current status and beyond Andreas von Deimling, Heidelberg/DE  Plenary Session 1 – Immunogenicity and immunotherapy Room: A3+A4
14:45 – 15:25 15:30 – 16:55	Room: A3+A4  Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Opening Lecture Room: A3+A4  Chairs: Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Brain Tumor Classification – From WHO 2016 to current status and beyond Andreas von Deimling, Heidelberg/DE  Plenary Session 1 – Immunogenicity and immunotherapy Room: A3+A4  Chairs: Gaetano Finocchiaro, Milan/IT, Tobias Weiss, Zurich/CH  Preclinical aspects of immunogenicity in gliomas
<b>14:45 - 15:25 15:30 - 16:55</b> 15:30 - 15:50	Room: A3+A4  Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Opening Lecture Room: A3+A4  Chairs: Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Brain Tumor Classification – From WHO 2016 to current status and beyond Andreas von Deimling, Heidelberg/DE  Plenary Session 1 – Immunogenicity and immunotherapy Room: A3+A4  Chairs: Gaetano Finocchiaro, Milan/IT, Tobias Weiss, Zurich/CH  Preclinical aspects of immunogenicity in gliomas Michael Platten, Mannheim/DE  Clinical aspects on immunotherapy targets in glioma
14:45 - 15:25 15:30 - 16:55 15:30 - 15:50 15:50 - 16:10	Room: A3+A4  Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Opening Lecture Room: A3+A4  Chairs: Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE  Brain Tumor Classification – From WHO 2016 to current status and beyond Andreas von Deimling, Heidelberg/DE  Plenary Session 1 – Immunogenicity and immunotherapy Room: A3+A4  Chairs: Gaetano Finocchiaro, Milan/IT, Tobias Weiss, Zurich/CH  Preclinical aspects of immunogenicity in gliomas Michael Platten, Mannheim/DE  Clinical aspects on immunotherapy targets in glioma Michael Weller, Zurich/CH  CAR T-cell therapy of brain tumours: status quo and quo vadis?



15:30 – 16:55	Plenary Session 2 – Nurse session Room: A2
	Chairs: Ingela Oberg, Cambridge/UK; Joachim Steinbach, Frankfurt/DE
15:30 – 15:50	Goings-On - a personalized monitor app for patients and families Petra Hoogendoorn, Weesp/NL
15:50 – 16:10	Use of intraoperative neuromonitoring in modern neurosurgery Oliver Schnell, Freiburg/DE
16:10 – 16:30	Minimising treatment toxicity  Emilie Le Rhun, Lille/FR
16:30 – 16:50	Interdisciplinary rehabilitation Anders Hansen, Odense/DK
15:30 – 16:55	Plenary Session 3 – Pediatric neuro-oncology Room: C1-C3
	Chairs: Didier Frappaz, Lyon/FR, Stefan Holm, Stockholm/SE
15:30 – 15:50	Neuropathology and classification of pediatric brain tumors  Cynthia Hawkins, Toronto/CA
15:50 – 16:10	Metylation classification in pediatric brain tumors  David Jones, Heidelberg/DE
16:10 – 16:30	International pediatric brain tumor trials – a role model for adult neuro-oncology Olaf Witt, Heidelberg/DE
16:30 – 16:50	Diffuse midline gliomas  Jacques Grill, Paris/FR
17:00 – 18:00	Poster Viewing I with authors – with wine and cheese
19:00 – 22:00	Youngsters Networking Event in the Conference Lounge in the Radisson Blu Royal Viking









#### Saturday, October 13

08:00 - 08:55	Wake up Session 4 – Novel approaches of molecular tumor classification Room: A3 + A4
	Chairs: Max Kros, Rotterdam/NL; Silvia Marino, London/UK
08:00 – 08:17	Alternate approaches to grading of IDH-mutant astrocytoma  Andreas von Deimling, Heidelberg/DE
08:17 – 08:34	Novel approaches based on Nanopore Sequencing Philipp Euskirchen, Berlin/DE
08:34 – 08:51	Novel radiogenomic approaches for glioma diagnostics Alexander Radbruch, Heidelberg/DE
08:00 - 08:55	Wake up Session 5 – Trial design and outcome measures Room: A2
	Chairs: Annika Malmström, Linkoeping/SE; Michael Weller, Zurich/CH
08:00 – 08:17	Molecularly informed trial designs (umbrella/basket trials)  Wolfgang Wick, Heidelberg/DE
08:17 – 08:34	Patient centered outcome Roger Henriksson, Umeå/SE
08:34 – 08:51	Near – randomised studies – a valuable tool in neuro-surgery studies Ole Solheim, Trondheim/NO
08:00 - 08:55	Wake up Session 6 – Enhancing patient care Room: C1-C3
	Chairs: Linda Dirven, Leiden/NL; Lena Sharp, Stockholm/SE
08:00 – 08:17	Early palliative care  Andrea Pace, Rome/IT
08:17 – 08:34	Neuropsychology: enhancing patient care Florien Boele, Leeds/UK
08:34 – 08:51	Mood and behaviour disorders  Ally Rooney, Edinburg/UK
09:00 - 10:20	Meet the expert Session 4 – CNS Metastasis: from basic science to clinical trials Room: A3 + A4
	Chairs: Sara Kinhult, Lund/SE; Riccardo Soffietti, Turin/IT
09:00 – 09:20	CNS Metastasis: molecular pathways to clinical trials Riccardo Soffietti, Turin/IT
09:20 – 09:40	Tumor invasion Rolf Bjerkvig, Bergen/NO
09:40 - 10:00	Molecular divergence how to approach?  Priscilla Brastianos, Boston/US
10:00 – 10:20	How to optimize imaging for the evaluation of responses to treatments? Marion Smits, Rotterdam/NL









09:00 - 10:20	Meet the expert Session 5 – Update in the management of meningioma and benign tumours Room: A2
	Chair: Roland Goldbrunner, Cologne/DE
09:00 – 09:20	Molecular markers in the decision making? Felix Sahm, Heidelberg/DE
09:20 – 09:40	Diagnosis and treatment Tiit Mathiesen, Copenhagen/DK
09:40 – 10:00	Supportive care in the short term and long term  Martin Taphoorn, The Hague/NL
10:00 – 10:20	What next? Matthias Preusser, Vienna/AT
10:20 – 10:50	Coffee break
10:50 - 12:45	Oral Session 3 – Molecular genetics and epigenetics Room: A3 + A4
	Chairs: Beatrice Amélie Darlix, Montpellier/FR; Beatrice Melin, Umeå/SE
10:50 – 11:15	Key Lecture Beatrice Melin, Umeå/SE
11:15 – 11:27	IDH-wild type grade II gliomas: a retrospective series of AINO (Italian Association of Neuro-Oncology)  Francesco Bruno, Turin/IT
11:27 – 11:39	The origin of humanglioblastoma (IDH wildtye) is not the location of the tumor but the subventricular zone Seok-Gu Kang, Seoul/KR
11:39 – 11:51	Radiological characteristics and natural history of adult IDH wild type astrocytomas with TERT promoter mutations  Jérôme Honnorat, Lyon/FR
11:51 – 12:03	Intra-tumour DNA methylation heterogeneity in glioblastoma Sandra Ferreyra Vega, Gothenburg/SE
12:03 – 12:15	Dynamic insights into the cellular heterogeneity of malignant gliomas Ruifan Xie, Heidelberg/DE
12:15 – 12:27	Development and validation of a DNA methylome-based predictor of meningioma recurrence and meningioma recurrence score Farshad Nassiri, Toronto/CA



10:50 – 12:45	Oral Session 4 – Supportive care Room: A2
	Chairs: Johan Koekkoek, Leiden/NL; Ingela Oberg, Cambridge/UK
10:50 – 11:05	Key Lecture Johan Koekkoek, Leiden/NL
11:15 – 11:27	A risk calculator to predict the need for an intervention within a patient's estimated lifetime for incidentally-found asymptomatic meningiomas Abed Islim, Liverpool/UK
11:27 – 11:39	The long-term disease burden of meningioma patients: results on health-related quality of life, cognitive function, anxiety and depression Amir H. Zamanipoor Najafabadi, Leiden/NL
11:39 – 11:51	The BReMen trial: Patients with benign meningioma - is rehabilitation really necessary? Almuth Kessler, Wuerzburg/DE
11:51 – 12:03	Interventions to help support caregivers of people with a brain or spinal cord tumour - a Cochrane systematic review Florien Boele, Leeds/UK
12:03 – 12:15	Working memory deficits in brain tumor patients are related to reduced default mode inhibition Irena Schouwenaars, Tilburg/NL
12:15 – 12:27	Does radiation target volume affect health-related quality of life in patients with low grade glioma on the short-term? - a secondary analysis of the EORTC 22033-26033 trial Clemens Seidel, Leipzig/DE
10:50 – 12:45	Oral Session 5 – Pediatric brain tumors Room: C1-C3
	Chair: Stefan Pfister, Heidelberg/DE
10:50 - 11:05	
10:50 - 11:05	Key Lecture Stefan Pfister, Heidelberg/DE
11:15 – 11:27	
	Stefan Pfister, Heidelberg/DE  Molecular subgroups of low- and high-grade gliomas diagnosed in the first year of life
11:15 – 11:27	Stefan Pfister, Heidelberg/DE  Molecular subgroups of low- and high-grade gliomas diagnosed in the first year of life  Ana Guerreiro Stücklin, Toronto/CA  FGFR a novel target in malignant pediatric ependymoma
11:15 – 11:27 11:27 – 11:39	Stefan Pfister, Heidelberg/DE  Molecular subgroups of low- and high-grade gliomas diagnosed in the first year of life  Ana Guerreiro Stücklin, Toronto/CA  FGFR a novel target in malignant pediatric ependymoma  Daniela Loetsch, Vienna/AT  Imaging comparative analysis of intracranial meningiomas in adult and pediatric NF2 patients
11:15 - 11:27 11:27 - 11:39 11:39 - 11:51	Stefan Pfister, Heidelberg/DE  Molecular subgroups of low- and high-grade gliomas diagnosed in the first year of life  Ana Guerreiro Stücklin, Toronto/CA  FGFR a novel target in malignant pediatric ependymoma  Daniela Loetsch, Vienna/AT  Imaging comparative analysis of intracranial meningiomas in adult and pediatric NF2 patients  Peng Li, Beijing/CN  Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals
11:15 - 11:27 11:27 - 11:39 11:39 - 11:51 11:51 - 12:03	Stefan Pfister, Heidelberg/DE  Molecular subgroups of low- and high-grade gliomas diagnosed in the first year of life  Ana Guerreiro Stücklin, Toronto/CA  FGFR a novel target in malignant pediatric ependymoma  Daniela Loetsch, Vienna/AT  Imaging comparative analysis of intracranial meningiomas in adult and pediatric NF2 patients  Peng Li, Beijing/CN  Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals  Aden Ka-yin Chan, Shatin/HK  Surveillance data demonstrates the tolerability of tumor treating fields in pediatric glioma patients
11:15 - 11:27 11:27 - 11:39 11:39 - 11:51 11:51 - 12:03 12:03 - 12:15	Molecular subgroups of low- and high-grade gliomas diagnosed in the first year of life Ana Guerreiro Stücklin, Toronto/CA  FGFR a novel target in malignant pediatric ependymoma Daniela Loetsch, Vienna/AT  Imaging comparative analysis of intracranial meningiomas in adult and pediatric NF2 patients Peng Li, Beijing/CN  Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals Aden Ka-yin Chan, Shatin/HK  Surveillance data demonstrates the tolerability of tumor treating fields in pediatric glioma patients Adrian Kinzel, Munich/DE  Issues and needs experienced by adolescent and young adult brain tumour survivors and their caregivers: A systematic review
11:15 - 11:27 11:27 - 11:39 11:39 - 11:51 11:51 - 12:03 12:03 - 12:15 12:15 - 12:27	Stefan Pfister, Heidelberg/DE  Molecular subgroups of low- and high-grade gliomas diagnosed in the first year of life  Ana Guerreiro Stücklin, Toronto/CA  FGFR a novel target in malignant pediatric ependymoma  Daniela Loetsch, Vienna/AT  Imaging comparative analysis of intracranial meningiomas in adult and pediatric NF2 patients  Peng Li, Beijing/CN  Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals  Aden Ka-yin Chan, Shatin/HK  Surveillance data demonstrates the tolerability of tumor treating fields in pediatric glioma patients  Adrian Kinzel, Munich/DE  Issues and needs experienced by adolescent and young adult brain tumour survivors and their caregivers: A systematic review  Emma Nicklin, Leeds/UK  Corporate Lunch Symposium



14:25 – 15:45	Plenary Session 4 – Management of adult and pediatric low grade gliomas Room: A3 + A4
	Chairs: Christine Marosi, Vienna/AT; Ryo Nishikawa, Saitama-Ken/JP
14:25 – 14:45	Update on molecular pathology  Monika Hegi, Epalinges/CH
14:45 – 15:05	Treatment – high risk or low risk adult patients?  Anthony Chalmers, Glasgow/UK
15:05 – 15:25	Surgical treatment Asgeir Jakola, Gothenburg/SE
15:25 – 15:45	Neuro-oncology in AYAs (Adolescent Young Adults): Joint efforts are worthwhile Didier Frappaz, Lyon/FR
14:25 – 15:45	Plenary Session 5 – Treatment resistance Room: A2
	Chairs: Carina Thomé, Heidelberg/DE; Martin van den Bent, Rotterdam/NL
14:25 – 14:45	Genetic/Epigenetic mechanisms Sevin Turcan, Heidelberg/DE
14:45 – 15:05	Cellular mechanisms/stem cells/DNA damage response Pim French, Rotterdam/NL
15:05 – 15:25	Tumor microtubes and therapy resistance of gliomas Frank Winkler, Heidelberg/DE
15:25 – 15:45	Clinical perspective? Roger Stupp, Chicago/US
14:25 – 15:45	Plenary Session 6 – Basic immunology Room: C1-C3
	Chairs: Alessia Pellerino, Turin/IT; Wolfgang Wick, Heidelberg/DE
14:25 – 14:45	Chairs: Alessia Pellerino, Turin/IT; Wolfgang Wick, Heidelberg/DE  Biomarker development for decision-making  Anna Berghoff, Vienna/AT
14:25 - 14:45 14:45 - 15:05	Biomarker development for decision-making
	Biomarker development for decision-making  Anna Berghoff, Vienna/AT  Preclinical models
14:45 – 15:05	Biomarker development for decision-making  Anna Berghoff, Vienna/AT  Preclinical models  Patrick Roth, Zurich/CH  Tumor derived T-cell ligandome
14:45 – 15:05 15:05 – 15:25	Biomarker development for decision-making  Anna Berghoff, Vienna/AT  Preclinical models  Patrick Roth, Zurich/CH  Tumor derived T-cell ligandome  Lukas Bunse, Heidelberg/DE  Translational immunology
14:45 - 15:05 15:05 - 15:25 15:25 - 15:45	Biomarker development for decision-making  Anna Berghoff, Vienna/AT  Preclinical models  Patrick Roth, Zurich/CH  Tumor derived T-cell ligandome  Lukas Bunse, Heidelberg/DE  Translational immunology  Pierre-Yves Dietrich, Geneva/CH  Better and knowledgeable patients – better decisions – better outcomes
14:45 - 15:05 15:05 - 15:25 15:25 - 15:45	Biomarker development for decision-making  Anna Berghoff, Vienna/AT  Preclinical models  Patrick Roth, Zurich/CH  Tumor derived T-cell ligandome  Lukas Bunse, Heidelberg/DE  Translational immunology  Pierre-Yves Dietrich, Geneva/CH  Better and knowledgeable patients – better decisions – better outcomes  Room: A3 + A4
14:45 - 15:05 15:05 - 15:25 15:25 - 15:45 <b>15:50 - 17:15</b>	Biomarker development for decision-making  Anna Berghoff, Vienna/AT  Preclinical models  Patrick Roth, Zurich/CH  Tumor derived T-cell ligandome  Lukas Bunse, Heidelberg/DE  Translational immunology  Pierre-Yves Dietrich, Geneva/CH  Better and knowledgeable patients – better decisions – better outcomes  Room: A3 + A4  Chairs: Roger Henriksson, Umeå/SE; Kathy Oliver, Tadworth/UK  The preferences of the patients and spouses

16:44 - 17:15

#### Poster Viewing II with authors - with wine and cheese

19:00 - 23:00 EANO Evening in the Grand Hôtel

Discussion

Marit Karlsson, Linkoeping/SE



## **SUNDAY, OCTOBER 14**

#### Sunday, October 14

08:30 - 09:25	EANO General Assembly Room: C1-C3
09:30 – 10:30	Ethical issues Room: C1-C3
09:30 – 09:48	Chairs: Roger Henriksson, Umeå/SE; Wolfgang Wick, Heidelberg/DE Ethical Issues around capacity to consent to treatment Robin Grant, North Berwick/UK
09:48 – 10:06	Euthanasia and brain tumour patients  Martin Taphoorn, The Hague/NL
10:06 – 10:24	Quality of life – Quality of death Carol Tishelman, Stockholm/SE
09:30 - 10:30	Experimental models Room: C4
09:30 - 09:48	Chairs: Patrick Roth, Zurich/CH; Frank Winkler, Heidelberg/DE Preclinical models and experimental therapy Rolf Bjerkvig, Bergen/NO
09:48 – 10:06	HGCC, an open resource of patient-derived glioblastoma cell models: current status and future directions  Lene Uhrbom, Uppsala/SE
10:06 - 10:24	PDX for drug development  Björn Scheffler, Essen/DE
10:30 – 11:15	Coffee break LEVEL 2
10:35 – 11:00	EORTC brain tumor studies Room: C1-C3 Michael Weller, Zurich/CH
11:10 – 12:35	EANO Youngster session – Perspectives in neuro-oncology Room: C1-C3
11:10 – 11:30	Chairs: Matthias Preusser, Vienna/AT; Carina Thomé, Heidelberg/DE How EANO can impact your career development? Wolfgang Wick, Heidelberg/DE
11:30 – 11:50	Basic Science as a driver of neuro-oncology research  Walter Berger, Vienna/AT
11:50 – 12:10	Dos and don't's in clinical trial design Roberta Rudà, Turin/IT
12:10 – 12:30	Making science count: How can I conduct clinically meaningful research? Joachim Steinbach, Frankfurt/DE









## **SUNDAY, OCTOBER 14**

11:10 – 12:10	Oral Session 6 – General clinical neuro-oncology Room: C4
	Chairs: Ulrich Herrlinger, Bonn/DE; Hanna Mäenpää, Helsinki/Fl
11:10 – 11:22	Glioma anatomic location and clinical phenotype relate to regional healthy brain network signature  Linda Douw, Amsterdam/NL
11:22 – 11:34	Identifying molecular subtypes of non-enhancing glioma using MRI perfusion and diffusion parameters  Marion Smits, Rotterdam/NL
11:34 – 11:46	Radiomics and machine learning on [18F]FET PET and T1ce MRI discriminate between low-grade and high-grade glioma Stijn Bonte, Ghent/BE
11:46 – 11:58	NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas <i>Michael Platten, Mannheim/DE</i>
11:58 – 12:10	Randomized phase III trial comparing GAMMA KNIFE (GK) and LINAC based (EDGE) radiosurgery for brain metastases from solid tumors: results from the GADGET trial Pierina Navarria, Milan/IT
12:40 – 13:00	Awards & Closing remarks – from president to president Room: C1-C3

Wolfgang Wick, Heidelberg/DE









### **SIDE MEETINGS**

As per date of printing.

#### Wednesday, October 10

09:00 - 11:00	EORTC Steering Committee Meeting *	Room C4
12:00 - 16:30	EORTC General Assembly *	Room C4
17:00 - 18:30	FORTC - 1709 / CCTG CF.8 Trial Meeting *	Room C4

#### Thursday, October 11

10:00 - 14:00	EANO Board Meeting *	Room 26
14:30 - 15:30	EORTC Meningioma Committee Meeting *	Room 26
16:00 - 16:45	EORTC BTG CNS Metastasis Committee *	Room 26
17:00 - 18:00	ROAM / EORTC 1308 Investigators Meeting *	Room 26

#### Friday, October 12

12:50 - 14:20	EANO Palliative care task force Meeting *	Room 23
13:00 – 13:45	Editorial Board Meeting *	Room C4
13:00 – 14:30	EANO Youngsters Committee Meeting *	Room 26
17:00 - 18:00	Meet the Sponsors Meeting *	Room 26
17:00 – 18:00	PCNSLO1 Investigator Meeting *	Room 23
18:00 – 18:30	WFNOS Meeting *	Room 26
18:30 – 19:00	Meeting Chairs National Societies *	Room 26

#### Saturday, October 13

09:00 - 10:30	BTFC Meeting *	Room 26
12:50 - 14:50	Focus Group Conference Meeting *	Room 23
13:15 - 14:15	NOA Meeting *	Room 26

<sup>\*</sup> Closed Meeting







## SCIENTIFIC INFORMATION







Oral Presentations	4
Poster Viewing	6
Poster Tonics 2	7



#### **ORAL PRESENTATIONS**

#### **PUBLICATION OF ABSTRACTS**

Please note that your work will be published online on the website of the journal "Neuro-Oncology" and on the EANO website.

#### INFORMATION FOR ORAL PRESENTERS

The preview centre is located in the Room 27.

#### **SPEAKING TIME**

The chairpersons of your session will be strict in allowing no more than the time allotted to your paper. Remember to allow some time for the changeover of speakers and chairperson's introduction, and for questions and discussion.

Please rehearse your talk to make sure it will fit comfortably into the available time.

Please note that, as a rule, presenters can show a (final) slide with all acknowledgements, however, in view of the short time available, names cannot be read to the audience.

Please see the detailed programme for any time changes.

#### COMMERCIAL DISCLOSURE INFORMATION

Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide.

A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (eg. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

If you have nothing to disclose, please state "I have no commercial disclosure".

#### AWARDS FOR BEST ORAL PRESENTATIONS

The EANO proposes awards for the best oral presentations at the meeting.

- The Vienna Medical Academy Award for the best oral presentation for clinical aspects.
- The EANO Presentation Award for the best oral presentation for preclinical aspects.
- The EANO Presentation Award for the best oral presentation in nursing perspective.

All three winners will receive a money price of EUR 500,-. The EANO Scientific Committee has selected a number of candidates for the Oral Presentation Awards based on the their submission after peer review.



#### **ORAL PRESENTATIONS**

#### PROJECTION AND TECHNICAL SETTING

PowerPoint is the only communication tool available in all session halls.

The preview centre is located in the **Room 27.** 

- 1. Speakers are kindly asked to observe that only computers provided by the congress may be used for showing your presentations. **All PowerPoint presentations must be handed in at the preview centre.**
- 2. All presentations are loaded into a PowerPoint handling system that will store and distribute your presentation to the session hall in time for your session.
- 3. All PowerPoint presentations should be handed in at least 2 hours before the session starts.

The opening hours of the preview room are as follows:

- 4. Please check your presentation carefully on the preview room computer assigned by the staff before the final sign off.
- 5. The professional staff of the preview centre will load your presentation into the system so that it will be available on the computer in your session hall when you come to speak.
- 6. If you are doing more than one speech during the congress, you may upload all your presentations at the same time and they will be sent to their corresponding session halls at the time of your sessions.
- 7. The PowerPoint handling and distribution system is optimized for **MS PowerPoint (last version) and** "\*.pdf" (Adobe Acrobat)-files. The uploading of "DVD-Movies" is not supported.
- 8. The supported data media are: **CD**, **DVD** (as **Data-storage-medium**) and **USB-Memory Key**. You may want to carry a second key/CD as a back-up in case there is any insoluble technical problem. **All needed files** (including the movie files!) have to be saved on the data media. Presentations can also be taken off speakers notebooks at the Preview centre.
- 9. The fonts that are used in the presentations should be "Latin-based fonts". If the speaker needs special fonts, they should be stored as "embedded fonts" with the presentation (File -> save as "name of presentation" and under "tools" ->save options mark the checkbox "embed True type fonts" and select "embed all characters").
- 10. When using mathematical symbols please use these which are available under Latin fonts (unicode or DOS: Western Europe). These can be shown without any problems in Office 2007.
- 11. As format for embedded movies "MPEG2 movies" are preferred (but can also be \*.avi, \*.wmv ). If Codecs are used, the Code package DIVx in the current version, which can be found under www.divx.com, should be chosen.
- 12. Presentations should be saved as "\*.ppt", "\*.pptx" ( = PowerPoint) or "\*.pps", \*.ppsx" (=PowerPoint Slideshow) file and movies as separate files on the data media.
- 13. The computers and projectors will be set up and optimised for 1920 x 1080 resolution (ratio 16:9).

These guidelines should be seen as a matter of improving the effectiveness of the preview system and in consequence also the speakers comfort.



#### **POSTER VIEWING**

#### INFORMATION FOR POSTER PRESENTERS

#### POSTER VIEWING / SESSIONS (Poster Area)

Poster Viewing I

Poster Viewing II

Friday, October 12, 17:00-18:00

Poster Topic P01-P03

Saturday, October 13, 17:15-18:15

roster topic roll ros

Poster Topic P04-P05

#### Schedule for display, mounting and removal

Friday, October 12, 17:00-18:00

Poster Viewing I (P01-P03)

Poster mounting:

For those posters displayed in poster viewing I the poster mounting is possible on Friday, October 12, from 08:00-12:30 hrs. Posters within the poster viewing I will be on display on Friday, October 12 from 17:00-18:00 hrs.

Poster removal:

Friday, October 12 from 18:00-19:00 hrs.

Please note that posters not removed until October 12, 19:00 hrs, will be taken down and will not be stored or sent to the authors after the meeting.

Saturday, October 13, 17:15-18:15

Poster Viewing II (P04-P05)

Poster mounting:

For those posters displayed in poster viewing II the poster mounting is possible on Saturday, October 13, from 08:00-12:30 hrs. Posters within the poster viewing II will be on display on Saturday, October 13 from 17:15-18:15 hrs.

Poster removal:

Saturday, October 13 from 18:15-19:00 hrs

Please note that posters not removed until October 13, 19:00 hrs, will be taken down and will not be stored or sent to the authors after the meeting.

#### **Poster Board Number**

Poster authors should have received their poster board number by email. Please note that both poster numbers for both days will be shown on the poster board. First poster number is indicated for the poster on Friday, Poster Session I, and the second poster number is indicated for the poster on Saturday, Poster Session II.

#### **Presence at Posters**

Please note that the posters have been divided into two separate poster sessions. In order to enable discussion and interaction with other participants, it is mandatory for you or one of your group members to be present at your poster board during the according poster session.

#### **Poster Format**

The usable surface on the poster board is **90 cm width x 150 cm height** and posters should be in **portrait format**. Only adhesive tape can be used to mount posters. Material to mount the posters is provided.



#### **POSTER TOPICS**

#### **POSTER TOPICS**

P01	Glioma – clinical aspects	P01.001-169
P02	Other tumor – preclinical aspects	P02.01-17
P03	Nursing perspective	P03.01-07
P04	Glioma – preclinical aspects	P04.01-92
P05	Other tumor – clinical aspects	P05.01-93

#### **POSTER VIEWING**

#### Poster Viewing 1:

Friday, October 12, 2018 from 17:00-18:00 hrs

P01	Glioma – clinical aspects
P02	Other tumor – preclinical aspects
P03	Nursing perspective

#### Poster Viewing 2:


Saturday, October 13, 2018 from 17:15-18:15 hrs

P04	Glioma – preclinical aspects
P05	Other tumor – clinical aspects

#### **POSTER AWARDS**

The EANO proposes EANO Poster Awards for the best posters presented at the meeting. The three winners (one for clinical aspects, one for preclinical aspects, one for nursing perspective) will receive a price money of EUR 500,-. The EANO Scientific Committee has selected a number of candidates for the EANO Poster Awards based on the their submission after peer review. Candidate posters can be identified by a star after the poster number.





## abbvie

AbbVie-Sponsored Symposium at the 13th Meeting of the European Association of Neuro-Oncology

## CURRENT PERSPECTIVES ON TREATMENT-RELATED CHALLENGES IN GLIOBLASTOMA

Chaired by Andrew Lassman, who will be joined by Mustafa Khasraw and Matthias Preusser

12:50–14:20, 13 October 2018 Room A2, Stockholm Waterfront Congress Center

https://www.abbvie.com/

## CORPORATE SYMPOSIA







Friday, October 12, 12:50 - 14:20 hrs Saturday, October 13, 12:50 - 14:20 hrs



#### **CORPORATE SYMPOSIA**

#### Corporate Symposium 1 – Novocure

#### Glioblastoma therapy with Tumor Treating Fields (Optune®)

Date: Friday, October 12 Time: 12:50 – 14:20 hrs

Room: A2



#### Roger Henriksson

Professor, Chief Physician, Chairmen for the Swedish Society for Treatment of CNS tumors, President EANO 2018 Meeting

#### Speaker:

#### PD Dr. Patrick Roth

Leading physician, Clinic for Neurology, University Hospital Zürich, Switzerland

#### Prof. Dr. Dr. Ghazaleh Tabatabai

Head of the Interdisciplinary Division of Neurooncology University Hospital Tübingen, Germany

#### Prof. Dr. Oliver Bähr

Leading physician, Center for Neurology and Neurosurgery, University Hospital Frankfurt, Germany

13:00 – 13:05	Introduction Roger Henriksson, Professor, Chief Physician
13:05 – 13:25	TTFields – Mechanism of action and additional preclinical data PD Dr. Patrick Roth
13:25 – 13:45	EF-14 study - subsequent subgroup analyses and Quality of Life data <i>Prof. Dr. Dr. Ghazaleh Tabatabai</i>
13:45 – 14:05	Overview and outlook of TTFields in other cancer types Prof. Dr. Oliver Bähr
14:05 – 14:20	Q&A





#### **CORPORATE SYMPOSIA**

#### Corporate Symposium 2 – AbbVie, Inc.

#### Current perspectives on treatment-related challenges in glioblastoma

Date: Saturday, October 13 Time: 12:50 – 14:20 hrs

Room: A2

Chaired by *Andrew Lassman*, who will be joined by *Mustafa Khasraw* and *Matthias Preusser* 

Welcome and introduction

Andrew Lassman Chair (US)

EGFR in glioblastoma: Biology and therapeutic approaches *Andrew Lassman (US)* 

Relevance of imaging & molecular biomarkers in glioblastoma *Mustafa Khasraw (AU)* 

Current and upcoming treatment approaches in glioblastoma *Matthias Preusser (AT)* 

Panel discussion

AII

Closing remarks

Andrew Lassman (US)







12. OCT 2018 12.50 - 14.20 SCIENTIFIC LUNCHTIME SYMPOSIUM Glioblastoma therapy with Tumor Treating Fields (Optune®)

**EXPERIENCE** > 8000 **GBM PATIENTS TREATED** TO DATE GLOBALLY

OPTUNE® + TMZ HAS BEEN PROVEN TO PROVIDE LONG-TERM QUALITY SURVIVAL TO PATIENTS WITH NEWLY DIAGNOSED GBM 2,3,4

**AVAILABILITY** >260 **CERTIFIED MEDICAL CENTERS IN EUROPE** 



The updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers now include alternating electric field therapy (Optune) in combination with temozolomide (TMZ) following maximal safe resection and standard brain radiation therapy with concurrent TMZ as Category 1 recommended treatment option for patients with newly diagnosed supratentorial glioblastoma (GBM) and good performance status.\* There is uniform NCCN consensus for this recommendation based on high-level evidence.

- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. V.1.2018.
- © 2018 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed March 20, 2018. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. Stupp R. et al. JAMA. 2017;318(23):2306-2316. doi:10.1001/jama.2017.18718
  Taphoorn MJB. et al. JAMA Oncol. 2018;4(4):495-504. doi:10.1001/jamaoncol.2017.5082
- Patient-reported data collected per EORTC QLQ-C30 at baseline and Months 3, 6, 9, and 12. The 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).
- The NCCN defines good performance as Karnofsky Performance Score (KPS)  $\geq$ 60. The trial for which the IFU is based used an eligibility criteria of KPS  $\geq$ 70. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use



## INFORMATION







Networking Events	34
General Information	.37
Registration Fees	42
Spansor & Exhibitor Listing	15



#### **NETWORKING EVENTS**

#### **Networking Event**

Stockholm City Hall Thursday, October 11, 2018

Start: 18:00 hrs

Address: Hantverkargatan 1, 111 52 Stockholm

The Welcome Reception will take place at the Stockholm City Hall, a venue approximately 750 m distance of the Stockholm Waterfront Congress Centre. Spend a nice evening with your colleagues while enjoying a smörgåsbord buffet and drinks.

We kindly thank Stockholm City and the County Council for hosting the reception.

Please note that advance registration is mandatory in order to receive a ticket!

For regular participants: included in the registration fee

Dress code: casual

Participation is included in the registration fee but registration for the event is necessary in advance.

No sponsoring is used to fund any part of the evening.

Please note that <u>no</u> transportation will be provided by the conference organiser.

The Stockholm City Hall is only a 10 min walk away.



© www.depositphotos.com - Stockholm City Hall



# **NETWORKING EVENTS**

## **Youngster Networking Event**

Conference Lounge (in the Radisson Blu Royal Viking)

Friday, October 12, 2018

Start: 19:00 hrs

Address: Radisson Blu Royal Viking, Vasagatan 1, 111 20 Stockholm

Join the EANO Youngster Networking Event and socialize with other young scientist and enjoy a nice evening with drinks and food. Please note that seats are limited and advance registration is mandatory in order to receive a ticket!

Ticket: EUR 5,- (incl. VAT)

Dress code: casual



© www.radissonblu.com/de/royalvikinghotel-stockholm

#### **EANO XIII Evening**

**Grand Hôtel** 

Saturday, October 13, 2018

Start: 19:00 hrs

Address: Södra Blasieholmshamnen 8, 103 27 Stockholm

The EANO XIII Evening will take place in the Grand Hôtel. Enjoy a wonderful evening with dinner.

Please note that seats are limited and advance registration is mandatory in order to receive a ticket!

Regular participants / extra ticket: EUR 95,- (incl. VAT) per person Nurse / AHP / PhD Student / Resident / Trainee\*: EUR 50,- (incl. VAT) per person

\*only applicable with adequate fee.



Dress code: formal

Please note that <u>no</u> transportation will be provided by the conference organiser and you will need to make your own way to the evening venue.

© www.depositphotos.com - Grand Hôtel Stockholm



# Leksell Gamma Knife® Icon™

# The clear choice for intracranial radiosurgery

- Clinical confidence
- Outstanding performance

Stand out with the best



Leksell Gamma Knife® Icon™ is not available for sale in all countries.

Focus where it matters. elekta.com/icon



#### **BADGES**

Participants should collect their name badge from the conference registration desk. Since only registered participants will be permitted to attend the scientific sessions, the exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.

Lost badges can be replaced at the registration desk. However, a handling fee of EURO 50.- incl. VAT will be charged.

#### **BANK SERVICES - MONEY MATTERS**

Banks are generally open from Monday to Friday from 09:00 – 15:00, on Thursdays until approximately 18:00 (closed on Saturdays and Sundays). There are multiple bank machines (ATMs) open 24 hours a day throughout the city which accept all major international bankcard.

The official currency of Sweden is the Swedish Krona (SEK, kr).

#### **CAR PARKING**

There is only very limited car parking space outside the venue. Find a map for car parking here: https://www.eano.eu/fileadmin/content/EANO\_Meetings/EANO\_2018/2018\_EANO\_Car\_parking\_near\_SWCC.pdf

#### **CERTIFICATE OF ATTENDANCE**

If you want to be accredited with CME credits please get your badge scanned every day at the registration desk. After completion of the post-congress evaluation form, you will receive your Certificate of Attendance via e-mail. The Certificate of Attendance will indicate the number of CME credits that correspond with your badge scans.

#### **CLIMATE**

The average temperatures mid of October in Stockholm are 10°C (high) and 5°C (low). The average number of rainy days is 15 with an average rainfall of 50 mm in October.

#### **CLOAKROOM AND LUGGAGE**

A cloakroom and luggage storage facilities are available in the congress venue.

#### **CME CREDITS**

see page 4

#### **COFFEE BREAKS**

During the morning session breaks, refreshments (coffee, tea and pastries) will be served free of charge to participants wearing name badges in the exhibition area.

#### **CURRENCY**

The official currency in Sweden is the Swedish Krona (SEK, kr). 1 SEK = 0.096 EUR = 0.085 GBP = 0.11 USD = 0.15 CAD = 12.28 JPY = 0.11 CHF = 0.16 AUD as per September 10, 2018

#### **DRINKING WATER**

The tap water in Stockholm can be used without concern.



#### **ELECTRICITY SUPPLY**

The power sockets in Sweden are of type F. The standard voltage is 230 V (50 Hz). Most electric outlets adhere to the continental standard (Schuko). You might check here if you need a power plug adapter: www.power-plugs-sockets.com

#### **EMERGENCY SERVICES**

European Emergency Number: 112 (Alternatively: Police – 117)

#### **EXHIBITION OPENING HOURS**

Thursday, October 11, 2018	09:00 - 17:00 hrs
Friday, October 12, 2018	09:00 - 18:00 hrs
Saturday, October 13, 2018	09:00 - 18:15 hrs

#### **INSURANCE**

In registering for the EANO 2018 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance.

#### INTERNET

Internet stations will be available in the exhibition area.

WIFI is available in all areas.

The access codes are: Network: EANO2018 Password: eano2018

#### **LANGUAGE**

The official language of the congress will be English (no simultaneous translation).

#### **LUNCH AND REFRESHMENTS**

During the lunch breaks, a light lunch will be offered free of charge to participants wearing name badges.

#### **STOCKHOLM**

Stockholm is located where the Baltic Sea meets Lake Mälaren and stretches across fourteen islands connected by 57 bridges, earning the Swedish capital the nickname "Beauty on the Water". Stockholm is an attractive capital that offers something for everyone: culture, nature, indulgence and an excellent infrastructure. Furthermore, the great transportation network in Sweden and to the whole Nordic area gives the possibilities to taste an interesting and beautiful part of Europe. It hosts the annual Nobel Prize ceremonies and banquet at the Stockholm Concert Hall and Stockholm City Hall.

www.visitstockholm.com

#### **MESSAGE BOARD**

A message board will be available in the exhibition area.



#### **PHARMACIES**

Regular pharmacy opening hours are weekdays from 10.00-18:00 hrs.

24-hour pharmacy: Apotek C.W. Scheele, Klarabergsgatan 64, Stockholm (located across from the Central Railway Station, near Åhlens Department Store, Tel: 0771 – 450 450)

Emergency Hospitals can be found here:

www.yourlivingcity.com/stockholm/essentials/hospitals-emergency-clinics-stockholm

#### **POSTERS**

see page 26

#### **PREVIEW CENTRE**

The preview centre is located in the Room 27 (Level 2).

#### PROGRAMME CHANGES - ACCESS TO SESSIONS

The conference organisers reserve a right to modify the programme and cannot assume any liability for changes in the programme due to external or unforeseen circumstances. No refunds can be granted in case of cancellation of speakers, lack of space in the conference room or any other incidents during the conference which are beyond the control of the conference organiser.

#### **PUBLIC TRANSPORTATION**

Stockholm has an excellent Public Transport System which is very effective. The underground train is the easiest way to get around the town. Tickets can be purchased at SL Centers, underground ticket booths, newsagent kiosks, via SMS or via the SL app. It's not possible to pay cash for tickets in Stockholm. https://sl.se/en/getting-around/

#### **REGISTRATION DESK OPENING HOURS**

Wednesday, October 10:	15:00 - 19:30 hrs
Thursday, October 11:	08:00 – 17:30 hrs
Friday, October 12:	07:30 – 18:15 hrs
Saturday, October 13:	07:30 – 18:30 hrs
Sunday, October 14:	08:15 – 12:45 hrs

#### SAFETY - CRIME

Stockholm remains a relatively safe, secure city. However, use of common sense is (always) required, as in any large city. Experience has shown that some basic precautionary measures should always be kept in mind in any city:

- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a copy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag or purse. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference centre.
- In heavily frequented tourist zones and the metro at rush hour, be aware of attemps of scam and pickpocketing.
- Do not respond to anybody unknown to you who comes up to you on the street engaging you in a conversation, no matter how safe they appear to be.



#### **SHOPS**

Shops in Stockholm are normally open on Monday to Friday from 09:00 until as late as 18:00 and from 10:00 until 15:00 or later on Saturdays. However, an increasing number of stores are now choosing to open on Sundays and extend their hours during the week.

#### SITE SEEING IN STOCKHOLM

The most important sights such as the Old Town (Gamla Stan), Djurgården (island), the different gardens and parks, the beautiful monuments are all located in the centre of Stockholm. There are also many museums such as the Vasa Museum, ABBA Museum, the Swedish National Museum... There is an Oper, a lot of different restaurants and café where you can have a hot drink.

#### **SMOKING POLICY**

The EANO 2018 is officially a "No-smoking-Conference".

Note that smoking is banned in public buildings, restaurants and bars.

#### **STAFF**

Should you have any questions; the conference staff recognisable by a neon yellow lanyard will be pleased to help you.

#### **TAXIS**

Taxi prices are not regulated in Sweden; they may vary greatly. It is the customer's responsibility to check prices beforehand. Check the price on the yellow-and-white label, which is usually on the rear door window, before entering the vehicle.

View available taxi companies here: www.visitstockholm.com/good-to-know/taxi/

#### **TELEPHONE CALLS**

The country code of Sweden is 46 and the Stockholm city code is 8.

#### **TIPPING**

Tips are not obligatory, but they are welcome. It is customary to round up to the nearest whole number (for example, the bill is 280 SEK, so you round up to 300 SEK).



#### **TOURIST INFORMATION**

At the Central Railway Station Klarabersviadukten 72, 111 64 Stockholm

Tel.: +46 731446826

E-Mail: matilda.jolin.w@savormedia.se www.savor-touristinformation.com

**Opening hours:** Mon - Fri 09:00 - 18:00 hrs, Sat - Sun 09:00 - 19:00 hrs

#### TRAVELLING - GETTING TO STOCKHOLM

#### By plane:

There are four airports with international traffic to and from Stockholm. The main airport is Stockholm Arlanda, located 40 km north of the city. There is a direct train going to the Stockholm Central Station: the "Arlanda-Express" (Departs every 15 min during the day and every 30 min during the night. The journey takes 20 minutes). There are also bus companies (Flygbussarna Airport Coaches or Flixbus).

The other airports are Bromma Airport (connection to the city with local buses), and Västeras and Skavsta, two airports located 100 km from Stockholm (connection to the city with Flygbussarna Airport Coaches).

#### By train:

Stockholm Central Station is the main railway station in the city of Stockholm and the largest railway station in Sweden. The Stockholm Central Station is located in the city centre. More than 200,000 travellers transit through the station daily, making it one of the busiest railway stations in Scandinavia. The station has all the facilities and services of a modern railway station. www.jernhusen.se

#### By bus:

Diverse bus companies offer bus trips to Sweden. With Eurolines, GoEuro or Flixbus you travel relaxed and cheaply from Berlin, Copenhaguen, Milan, Turin, Rome, Vienna, Paris, London, Helsinki, Oslo and other cities to Stockholm. Buses arrive to Stockholm City Terminalen near to the Stockholm Central Rail station. The Stockholm Old Centre is 15 min by feet (Gamla Stan) and the Central Rail Station is in the centre of the city.

#### V.A.T.

The standard V.A.T. rate in Sweden is 25%.

#### **VENUE**

Stockholm Waterfront Congress Centre Nils Ericsons Plan 4, Stockholm

www.stockholmwaterfront.com



# **REGISTRATION FEES**

#### **REGISTRATION**

Onsite registration is possible during the opening hours of the registration desk as follows:

Wednesday, October 10: 15:00 - 19:30 hrs Thursday, October 11: 08:00 - 17:30 hrs 07:30 - 18:15 hrs Friday, October 12: Saturday, October 13: 07:30 - 18:30 hrs Sunday, October 14: 08:15 - 12:45 hrs

#### **REGISTRATION FEES**

PAYMENT RECEIVED*	REDUCED RATE until July 22	REGULAR RATE from July 23 to August 31	LATE & ON-SITE RATE after August 31
EANO Member	EUR 475,-	EUR 560,-	EUR 635,-
Non Member	EUR 745,-	EUR 830,-	EUR 900,-
Nurse / AHP - EANO Member	EUR 160,-	EUR 160,-	EUR 215,-
Nurse / AHP - Non Member	EUR 250,-	EUR 250,-	EUR 310,-
PhD Student/ Resident/Trainee**	EUR 250,-	EUR 250,-	EUR 310,-
EANO-SNO Brain Tumor Club	EUR 100,-	EUR 100,-	EUR 100,-
EANO-SNO Brain Tumor Club (PhD Student/Resident/Trainee)	EUR 50,-	EUR 50,-	EUR 50,-
EANO XIII Educational Day	EUR 215,-	EUR 230,-	EUR 250,-
<b>Educational Day for Nurses</b> Nurses/ AHPs registered for the EANO meeting	EUR 0,-	EUR 0,-	EUR 0,-
<b>Educational Day for Nurses</b> All other persons (EANO delegates & outsiders)	EUR 50,-	EUR 50,-	EUR 50,-
Networking Event	Included in the registration fee		
Youngster Networking Event	EUR 5,-		
EANO Evening	Regular participant & accompanying ticket		PhD Student/ Resident/ Nurse/AHP
	EUR	95,-	EUR 50,-

All prices include 25% VAT.

#### Please note:

Pre-registration without payment of the registration fee is possible.

The onsite fee will then have to be paid at the registration desk (Credit card or cash).

What is covered by the registration fee?

- Admission to all scientific sessions
- Admission to exhibition
- Admission EANO Networking Event (free of charge but registration is mandatory!)
- Final programme
- Coffee/tea during breaks
- Light lunch

Please note that the day of payment is decisive for the registration fee, not the day of registration.

<sup>\*\*</sup> PhD Students, residents and trainees: Please provide a copy of a Student's ID or a confirmation signed by the head of department at the moment of your registration. Confirmations handed in at a later stage cannot be considered.



# **REGISTRATION FEES**

#### EANO - SNO Brain Tumor Club, October 10, 2018

What is a Brain Tumor Club? In our view, this would be the chance for all scientists to orally present their basic and translational research in a short format with lots of opportunity to discuss and interact with peers that are mainly lab-based and therefore do only in part represent the usual attendance of EANO.

#### **Registration Fees**

Regular registration: EUR 100,-

Reduced registration fee (for PhD Student, Resident, Trainee, Nurses, AHPs): EUR 50,-

Admission to the Special Lecture & Get Together on Wednesday October 10, 2018 is included.

#### EANO-EORTC Educational Day, October 10-11, 2018

The EANO Educational Course is done in collaboration with the EORTC and shares the format of the well perceived EANO/ESMO/EORTC training course. The course will be in English and will feature a series of well-known international experts in the field on all topics relevant for a detailed introduction to or update on neuro-oncology. The concept of the course allows all PhD students or residents to get a full insight into modern neuro-oncology.

If you wish to attend the Educational Day, please note that it is **NOT** included in the registration fee of the EANO 2018 Meeting. The Educational Day is subject to additional registration and costs.

#### REGISTRATION FEES (EDUCATIONAL DAY EANO-EORTC)

PAYMENT RECEIVED*	REDUCED RATE until July 22	REGULAR RATE from July 23 to August 31	LATE & ON-SITE RATE after August 31
EANO XIII Educational Day	EUR 215,-	EUR 230,-	EUR 250,-

All prices include 25% VAT.

What is included in the Educational Day fee?

- Special Lecture & Get together on Wednesday October 10, 2018 (free of charge but registration is mandatory!)
- Extra tickets for the Special Lecture & Get together can be purchased for EUR 48,- (incl. VAT) per ticket.
- · Admission to courses of your choice
- Syllabus
- Coffee/tea during breaks

<sup>\*</sup> Please note that the day of payment is decisive for the registration fee, not the day of registration.



# **REGISTRATION FEES**

#### **PAYMENT MODALITIES**

Payment of Registration fees, may be made by:

- Cash in EUR or SEK
- Credit Cards: Diners Club, Mastercard and Visa (only EUR).

#### **IMPORTANT**

The reduced registration fee was only applicable, if it has been paid to the congress account within the according deadlines. Registering without performing an actual payment automatically set your balance to the fee applicable onsite.

#### **PAYMENT DEADLINES**

Reduced Rate:	until July 22, 2018
Regular Rate:	July 23 - August 31, 2018
Late & On-site Rate:	after August 31, 2018

#### **CANCELLATIONS AND REFUNDS**

Notice of cancellation must be made in writing by email or fax to the congress office.

Registration fees may be refunded as follows:

Written cancellation received:

Within 48 hrs of credit card payment (until January 1,2018):
before July 22, 2018:
between July 23 and August 31, 2018:
after August 31, 2018:
no refund

The date of receipt of the email or fax ID was the basis for considering refunds.

Refunds will be made after the congress to your bank account.

The cancellation will not be effective until a written acknowledgement from the EANO 2018 Registration Department is received.

In the case of over-payment or double payment, refund requests must be made in writing and sent to the EANO 2018 Registration Department by email.

No refunds will be granted for unattended events or early termination of attendance, in case of cancellation of speakers, lack of space in the lecture room or any other incidents during the meeting, which are beyond the control of the meeting organisers.

No exceptions to the refund policy can be made, including health or family issues, however, we welcome substitute delegates at any time. By registering to the EANO 2018 participants agree that neither the organising committee nor the organising office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance. The conference fee does not include insurance.



# **SPONSOR & EXHIBITOR LISTING**

The European Association of Neuro-Oncology gratefully acknowledges the support of the following institutions, companies and organisations (as per date of printing).

### **EXHIBITORS**

**ABBVIE** 

**ACCURAY** 

**EANO** 

**ELEKTA** 

**IBTA** 

**MAGFORCE** 

**MEDAC** 

**NOVOCURE** 

ORBUS THERAPEUTICS INC

VARIAN



#### **SPONSORS**

**PLATINUM SPONSORS** 





**SILVER SPONSORS** 





THE NANOMEDICINE COMPANY

**OTHER SPONSOR** 









#### Coordination

EANO 2018 c/o WMA GmbH Alser Strasse 4 • 1090 Vienna • Austria t: +43 1 405 13 83 - 27 or 42 e: eano-meetings@eano.eu www.eano.eu


Layout: Barbara Biegl, www.biegl-grafik.at

Photo Credits: Unless otherwise indicated all pictures

© EANO – European Association of Neuro-Oncology

Copyright © 2018 EANO

All rights reserved. No part of this publication may be reproduced, distributed or transmitted without the prior written permission of EANO. Content as per date of printing. Some information may be subject to change.



# NEW APPROACH IN CANCER IREALMENT

# NanoTherm® Therapy

- Fighting cancer with nanomedicine
- NanoTherm® Therapy a unique approach for focal treatment of solid tumors
- Intra-tumoral application of superparamagnetic nanoparticles and later activation via alternating magnetic field
- European certification for treatment of brain tumors since 2010









Centre de Congrès Lyon, France

SAVE THE DATE

www.eano.eu